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doi:10.1016/j.jtcvs.2003.11.0351058 The Journal of Thoracic and CardBackground: The purpose of this study was to describe our institutional experience
in using inhaled prostacyclin as a selective pulmonary vasodilator in patients with
pulmonary hypertension, refractory hypoxemia, and right heart dysfunction after
cardiothoracic surgery.
Methods: Between February 2001 and March 2003, cardiothoracic surgical patients
with pulmonary hypertension (mean pulmonary artery pressure 30 mm Hg or
systolic pulmonary artery pressure 40 mm Hg), hypoxemia (PaO2/fraction of
inspired oxygen 150 mm Hg), or right heart dysfunction (central venous pressure
16 mm Hg and cardiac index 2.2 L · min1 · m2) were prospectively
administered inhaled prostacyclin at an initial concentration of 20,000 ng/mL and
then weaned per protocol. Hemodynamic variables were measured before the
initiation of inhaled prostacyclin, 30 to 60 minutes after initiation, and again 4 to 6
hours later.
Results: One hundred twenty-six patients were enrolled during the study period. At
both time points, inhaled prostacyclin significantly decreased the mean pulmonary
artery pressure without altering the mean arterial pressure. The average length of
time on inhaled prostacyclin was 45.6 hours. There were no adverse events attrib-
utable to inhaled prostacyclin. The average cost for inhaled prostacyclin was $150
per day. Compared with nitric oxide, which costs $3000 per day, the potential cost
savings over this period were $681,686.
Conclusions: Inhaled prostacyclin seems to be a safe and effective pulmonary
vasodilator for cardiothoracic surgical patients with pulmonary hypertension, re-
fractory hypoxemia, or right heart dysfunction. Overall, inhaled prostacyclin sig-
nificantly decreases mean pulmonary artery pressures without altering the mean
arterial pressure. Compared with nitric oxide, there is no special equipment required
for administration or toxicity monitoring, and the cost savings are substantial.
Because of a potential conflict of interest related to this manuscript on the part
of our editors, Dr David A. Fullerton served as guest section editor, assigned
reviewers, and made editorial decisions or recommendations leading to its
acceptance for publication.iovascular Surgery ● April 2004
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PPulmonary hypertension, right ventricular dys-function, and perioperative hypoxemia arecommon problems that necessitate treatmentin a cardiothoracic intensive care unit. Inhalednitric oxide (iNO) was the first agent shown tobe a selective pulmonary artery vasodilator,
and it has also been shown to improve oxygenation in
patients with acute lung injury and adult respiratory distress
syndrome (ARDS).1,2 Nitric oxide, however, has become
prohibitively expensive and has several associated toxicities
that necessitate monitoring, which further increases the
cost.3
In the search for a selective pulmonary artery vasodila-
tor, both as an alternative and possibly as a complement to
iNO, several drugs administered via the inhalational route
have been described in animal models and humans. These
include inhaled sodium nitroprusside, nitroglycerin, class 5
phosphodiesterase inhibitors (such as zaprinast and silde-
nafil), milrinone, prostaglandin E1 (PGE1; alprostadil), PGI2
(prostacyclin), and iloprost (the stable analog of PGI2).4 The
use of intravenous PGI2 was first described in 1978 in
canine experiments.5 As opposed to PGE1, PGI2 was shown
not to have any pulmonary inactivation and was therefore
10 times more potent than a systemic vasodilator, even
though its metabolite 6-keto-prostaglandin F1 had few
systemic vasodilator properties. However, intravenous
PGI2, as opposed to intravenous PGE1, became an impor-
tant pulmonary vasodilator in the treatment of pulmonary
hypertension.6 However, in some patients with pulmonary
hypertension, the intravenous doses required to decrease
pulmonary artery pressures (PAPs) are often so high that
significant systemic hypotension occurs. In 1993, Welte and
colleagues7 reported that inhaled PGI2 (iPGI2) resulted in
selective pulmonary artery vasodilation in dogs. It has been
shown to be as effective as iNO in reducing pulmonary
vascular resistance in heart transplant candidates,8,9 in de-
creasing PAPs in primary and secondary pulmonary hyper-
tension,10 and in improving right ventricular function in
animals with hypoxic pulmonary vasoconstriction11; it is
also effective as a selective pulmonary artery vasodilator,
with improvement in oxygenation in patients with
ARDS.12-14 Compared with iNO, it is less expensive, is
easier to administer, is relatively free of side effects, and
requires no special toxicity monitoring.
The manufacturer has not sought Food and Drug Admin-
istration (FDA) approval for inhalational administration of
PGI2. The objective of this case series was to report our
institutional experience with iPGI2 in critically ill cardio-
thoracic surgical patients. Our secondary aim was to deter-
mine whether it is easy to use during surgery as well as in
the intensive care setting and to perform a cost analysis
comparing it with iNO.
The Journal of ThoracicMethods
The Human Studies Committee at Washington University Medical
School approved the study, and all enrolled patients signed written,
informed consent. Before initiation of the study, the principal
investigator (E.J.) obtained an investigational new drug application
from the FDA. This was done so we could investigate a new route
of administration of a previously approved drug.
One hundred twenty-six patients (67 men and 59 women with
a mean age of 56  15 years) were enrolled in this prospective,
interventional study of iPGI2. The inclusion criteria were cardio-
thoracic surgery patients with pulmonary hypertension, right ven-
tricular dysfunction, or refractory hypoxemia in the perioperative
period. Pulmonary hypertension was defined as a mean PAP
(MPAP) 30 mm Hg or more or systolic PAP 40 mm Hg or more.
Right ventricular failure was defined as a central venous pressure
(CVP) 16 mm Hg or more and cardiac index less than 2.2 L ·
min1 · m2. Refractory hypoxemia was defined as a ratio of
arterial partial oxygen pressure to fraction of inspired oxygen
(PaO2/FIO2 ratio) less than 150 mm Hg. Clinicians first attempted
to improve oxygenation by conventional methods. These included
strategies such as: 1) increasing the inspired oxygen tension, 2)
optimizing functional residual capacity with the best positive end-
expiratory pressure (PEEP) and recruitment maneuvers, 3) opti-
mizing the inspiration-expiration ratio, 4) selecting the most ap-
propriate mode of mechanical ventilation, and 5) using
neuromuscular blockade when indicated. The exclusion criteria
were patients younger than 18 years of age, pregnant patients, and
those with a known allergy or sensitivity to PGI2 or the diluent
(glycine). Hemodynamic variables were measured before the ini-
tiation of iPGI2, 30 to 60 minutes after the initiation, and every 6
hours thereafter. The study was designed to optimize patient safety
and ease of use while maintaining clinician autonomy. Clinicians
were free to titrate inotropes, vasoconstrictors, or vasodilators to
maintain mean arterial blood pressure (MAP), cardiac output, or
both. Side effects attributable to the use of iPGI2 were recorded.
All adverse events were reported to the Human Studies Committee
and then reviewed by a data safety monitoring committee for a
further in-depth review.
PGI2 is supplied as a sodium salt of epoprostenol (Flolan;
Glaxo Wellcome Inc, Research Triangle Park, NC). It is reconsti-
tuted in 50 mL of glycine buffer diluent (sterile diluent for Flolan)
to a final concentration of 20,000 ng/mL. It is then nebulized by
using a continuous nebulizer system (MiniHEART nebulizer;
Westmed, Tucson, Ariz). This is attached to the inspiratory limb of
the ventilator circuit or via face mask with a Venturi attachment
for aerosolization. For continuous administration, a 60-mL syringe
of PGI2 (20,000 ng/mL) is attached to a standard intravenous pump
and delivered at a constant rate of 8 mL/h to the nebulizer cham-
ber. The nebulizer chamber is primed with 15 mL of the PGI2
solution, and at a nebulizing oxygen flow rate of 2 to 3 L/min,
approximately 8 mL/h is nebulized. The glycine buffer diluent is
“sticky,” and we therefore decided to empirically change filters on
the ventilator every 2 hours to prevent ventilator valve malfunc-
tion. To support continuous nebulization, a heated wire circuit was
added to the ventilator. The iPGI2 concentration was weaned by
50% every 2 to 4 hours until a concentration of 2500 ng/mL was
reached (20,000 to 10,000 to 5000 to 2500 ng/mL), as long as the
patient did not have a negative response. A negative response was
and Cardiovascular Surgery ● Volume 127, Number 4 1059
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or the PaO2/FIO2 ratio by 10%. Systemic arterial pressure was
closely monitored, and the PGI2 dose was adjusted accordingly if
a clinical change in blood pressure was observed.
The major aim of this study was to evaluate the immediate and
sustained effects of iPGI2 on PAPs in patients with pulmonary
hypertension, right ventricular dysfunction, and refractory hypox-
emia. Previous studies have shown reductions in MPAP of at least
8 mm Hg (SD, 7.5 mm Hg) with iPGI2. On the basis of these
findings, 9 patients would be required to demonstrate a mean
decrease in PAP of 8 mm Hg (SD, 8 mm Hg) with a power of 90%
and a P value of .05. With the large number of patients we were
planning to recruit (100), the study was adequately powered to
detect effects of iPGI2 on PAP in each subgroup.
The Shapiro-Wilke test of normality was used to assess the
distribution of the continuous data. Variables were normally dis-
tributed. Paired Student t tests were used to evaluate the changes
seen in hemodynamic and oxygenation parameters. The SPSS
Figure 1. Effect of iPGI2 on MPAP, MAP, the MPAP/M
smaller number of patients at the 4- to 6-hour time pe
at this time period are smaller because some of the
incomplete data.statistical package (SPSS, Chicago, Ill) was used for all analyses.
1060 The Journal of Thoracic and Cardiovascular Surgery ● AprA post hoc analysis of patients with refractory hypoxemia was
performed.
Results
One hundred twenty-six patients were prospectively en-
rolled during the study period. The demographics are shown
in Table 1. The average time on iPGI2 was 45.6 hours
(range, 0.1-390 hours). Tables 2 through 7 show the analysis
for the 3 groups of patients that were enrolled. At both time
points (after initiation and at 4-6 hours), iPGI2 significantly
decreased the MPAP. The ratio of MPAP to MAP improved
significantly at both time points. Further, no significant
changes were observed in MAP at the same time points,
demonstrating the selective pulmonary effects of iPGI2. The
effect of iPGI2 on all hemodynamic parameters is reported
in Tables 8 and 9. Although the entire group did not show
atio, and cardiac index for all patients: P < .001. The
are compared with their own baseline. The numbers
inal patients were no longer receiving iPGI2 or hadAP r
riods
origan improvement in the PaO2/FIO2 ratio, post hoc analysis
il 2004
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Pshowed that in patients with refractory hypoxemia, there
was a significant improvement in the PaO2/FIO2 ratio (Tables
2 and 3). The initial PaO2/FIO2 increased from 85  33 to
158  114 (P  .001). For those patients with refractory
hypoxemia who remained on the treatment at 4 to 6 hours,
the PaO2/FIO2 ratio increased from 95  36 to 186  111
(P  .001).
There was a substantial cost savings compared with iNO.
The total cost for administering iPGI2 is approximately
$150 per day. The cost for iNO is $125 per hour, or $3000
per day. Total patient hours of iPGI2 administration were
5740.50 hours. The total iPGI2 cost was $35,878, versus a
calculated nitric oxide cost of $717,564. This amounts to a
calculated cost savings of $681,686.
There were few adverse events attributable to iPGI2. No
patients complained of facial flushing. There was no signif-
icant systemic hypotension. There were no clinically signif-
icant bleeding events. Within 30 days, there were 2 re-
explorations for postoperative bleeding (2/126; 1.6%), 6
cases of renal failure (6/126; 1.6%), and 1 new stroke
(1/126; 0.8%). There were 2 perioperative cardiac arrests
(2/126; 1.6%). There was 1 serious adverse event related to
the use of the “sticky” glycine diluent. An exhalation valve
on a ventilator became stuck, and this resulted in significant
auto-PEEP and hypotension. The problem was diagnosed
early, and there were no sequelae. On several patients, the
mainstream end-tidal CO2 analyzers ceased to function be-
cause of excess moisture accumulation. The overall 30-day
mortality rate was 12.7%.
Discussion
Inhaled aerosolized PGI2 has been described in a number of
small human studies for use in patients with ARDS,12-15
primary and secondary pulmonary hypertension,10,16 and
right ventricular failure or dysfunction9,17 and to improve
oxygenation.18,19 It has also been shown to be as effective
as iNO.8,12,13,20-22 However, centers that use iPGI2 use it via
a non–FDA-approved route of administration. Similarly,
iNO used for indications other than pulmonary hypertension
is used for a non–FDA-approved indication. After obtaining
a FDA investigational new drug application, we set out to
document and demonstrate its efficacy, safety, ease of ad-
ministration, and cost in a large cardiothoracic surgical
operating room and intensive care unit. We found that iPGI2
was effective as a selective pulmonary artery vasodilator in
patients with pulmonary hypertension and right ventricular
dysfunction, and improved oxygenation in patients with
refractory hypoxemia. It acutely decreased PAPs while
MAP was maintained. This resulted in an improvement in
the MPAP/MAP ratio. Inhaled PGI2 was also effective in
improving oxygenation regardless of the etiology of hypox-
emia. In patients with poor oxygenation, iPGI2 not only
improved oxygenation, but was also effective as a pulmo-
nary vasodilator while maintaining MAP and cardiac out-
The Journal of Thoracicput. Our study also demonstrates that there did not seem to
be any appreciable tolerance to any of the beneficial effects
after 4 to 6 hours of administration.
Inhaled PGI2 binds to subunits of the prostaglandin
G/protein receptor, which results in an increase in cyclic
adenosine monophosphate,23 as opposed to iNO, which
results in an increase in cyclic guanosine monophosphate.3
Many of iNO’s associated toxicities are thought to be re-
lated to the increase in cyclic guanosine monophosphate
that interferes with normal cellular proliferation, including
DNA strand breaks and potential mutagenic base alter-
ations.3 PGI2 has a short half-life of 5 minutes. It is rapidly
hydrolyzed at acid or physiologic pH to 6-keto-prostaglan-
din F1,24,25 which has been shown to have few vasodilator
properties.5 As opposed to PGE1 (alprostadil), which is
commonly used to prevent reperfusion injury or as an in-
travenous pulmonary artery vasodilator in the perioperative
period, intravenous PGI2 is not inactivated in the pulmonary
circulation. Because of this lack of pulmonary inactivation,
PGI2 is 10 times more potent as a systemic vasodilator than
PGE1.5
As with iNO, there are theoretical concerns regarding the
potential antiplatelet effects of PGI2 and its metabolite 6-ke-
to-prostaglandin F1.24,26 Platelet/endothelial cell adhesion
is regulated by endothelial cell–derived mediators, includ-
TABLE 1. Demographics (n  126)
Variable Data
Age (y) (mean  SD) 56 15
Weight, (kg) (mean  SD) 77 22
Sex
Male 67
Female 59
Cardiac operation 78
CABG 17
CABG  valve 11
Valve 17
Heart transplantation 12
LVAD 15
Other* 6
Lung transplantation 43
Thoracic operation 5
Enrollment criteria†
Pulmonary hypertension 110
RV dysfunction 14
Refractory hypoxemia 32
CABG, Coronary artery bypass graft; LVAD, left ventricular assist device;
RV, right ventricular.
*Other cardiac operations included atrial septal defect repair, maze-atrial
septal defect, pulmonary thromboendarterectomy, post-extracorporeal
membrane oxygenator removal after redo-aortic valve replacement, tho-
racoabdominal aortic aneurysm repair, post– chest wound re-exploration.
†Note that some patients met more than 1 of the 3 inclusion criteria.ing PGI2 and endothelium-derived relaxing factor. PGI2
and Cardiovascular Surgery ● Volume 127, Number 4 1061
Cardiopulmonary Support and Physiology De Wet et al
CSPactivates platelet adenylate cyclase and augments cyclic
adenosine monophosphate formation by way of specific
membrane receptors. van Heerden and colleagues14 demon-
strated that even though significant levels of 6-keto-prosta-
glandin F1 could be demonstrated in patients receiving
iPGI2 for ARDS, there was no effect on platelet aggregation
as measured by the response to adenosine diphosphate. In a
double-blind, placebo-controlled randomized study over 4
to 6 hours of administration of iPGI2, Haraldsson and as-
sociates27 reported that even though antiplatelet effects
TABLE 2. Hemodynamic parameters for patients with refra
Variable Before iPGI2
PaO2/FIO2 ratio 85 33
MAP (mm Hg) 77 11
PAP (mm Hg) 32 9
MPAP/MAP ratio 0.43 0.13
CI (L · min1 · m2) 2.7 1.1
CVP (mm Hg) 17 6
Wedge (mm Hg) 21 4
PVR (dynes  s  cm5) 191 47
SVR (dynes  s  cm5) 1315 655
iPGI2, Inhaled prostacyclin; MAP, mean arterial blood pressure; PAP, pulmo
CVP, central venous pressure; PVR, pulmonary vascular resistance; SVR,
TABLE 3. Hemodynamic parameters for patients with refra
Variable Before iPGI2
PaO2/FIO2 ratio 95 36
MAP (mm Hg) 76 11
PAP (mm Hg) 32 7
MPAP/MAP ratio 0.44 0.11
CI (L · 1 · m2) 2.4 0.5
CVP (mm Hg) 18 5
Wedge (mm Hg) 20 4
PVR (dynes  s  cm5) 212 78
SVR (dynes  s  cm5) 1147 414
iPGI2, Inhaled prostacyclin; MAP, mean arterial blood pressure; PAP, pulmo
CVP, central venous pressure; PVR, pulmonary vascular resistance; SVR,
TABLE 4. Hemodynamic parameters for patients with pulm
Variable Before PGI2
PaO2/FIO2 ratio 300 184
MAP (mm Hg) 76 12
PAP (mm Hg) 36 9
PAP/MAP ratio 0.49 0.14
CI (L · min1 · m2) 2.6 0.9
CVP (mm Hg) 18 7
Wedge (mm Hg) 18 2
PVR (dynes  s  cm5) 358 164
SVR (dynes · s  cm5) 1199 483
iPGI2, Inhaled prostacyclin; MAP, mean arterial blood pressure; PAP, pulm
pulmonary vascular resistance; SVR, systemic vascular resistance.could be detected by in vitro measurements such as platelet
1062 The Journal of Thoracic and Cardiovascular Surgery ● Apraggregation and thromboelastography, these effects were
not clinically detected as measured by chest tube output and
bleeding times after on-pump cardiac surgery. On the basis
of these findings, we therefore did not monitor blood levels
of either PGI2 or its metabolite. Our results corroborate this
because the re-exploration rate for bleeding was low. In
contrast to the increasing bleeding times, there is also a
theoretical concern that when platelets are exposed to ex-
tended periods of PGI2 or its chemical analogs it may result
in a time- and dose-dependent desensitization of the pros-
28 28
y hypoxemia: baseline and after iPGI2
After iPGI2 n P value
158 114 27 .001
75 10 32 .331
28 9 26 .014
0.35 0.20 26 .039
2.6 0.7 13 .504
17 7 24 .358
17 2 2 .5
179 146 2 .892
1163 364 8 .297
rtery pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index;
mic vascular resistance.
y hypoxemia: baseline and after 4 to 6 h on iPGI2
4 to 6 h after n P value
186 111 17 .001
78 12 25 .465
26 9 22 .001
0.34 0.15 22 .001
2.6 0.6 10 .635
15 6 22 .015
16 0 2 .41
139 23 2 .307
1069 218 7 .708
rtery pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index;
mic vascular resistance.
ry hypertension: baseline and after the initiation of iPGI2
After PGI2 n P value
319 168 55 .322
78 11 109 .148
30 8 107 .001
0.40 0.12 107 .001
2.8 0.9 30 .054
18 8 78 .22
18 3 11 .933
246 122 11 .005
1093 390 19 .291
y artery pressure; CI, cardiac index; CVP, central venous pressure; PVR,ctor
nary a
systector
nary a
systeona
onartacyclin receptor. Darius and associates showed that
il 2004
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Pthere was an in vitro platelet PGI2 receptor desensitization
that caused a marked augmentation of platelet/endothelial
cell adhesion. This could theoretically cause thrombus for-
mation. Our data and safety monitoring committee reviewed
all adverse events and found no hematologic adverse events
attributable to iPGI2.
Inhaled PGI2 is a potent vasodilator.5 However, as in
other studies, we did not detect significant systemic hypo-
tension. It has subsequently been confirmed that iPGI2 has
no systemic hypotensive effects in doses up to 50 ng · kg1
1
TABLE 5. Hemodynamic parameters for patients with pulm
Variable Before PGI2
PaO2/FIO2 ratio 282 164
MAP (mm Hg) 76 11
PAP (mm Hg) 36 9
PAP/MAP ratio 0.48 0.13
CI (L · min1 · m2) 2.6 0.8
CVP (mm Hg) 19 7
Wedge (mm Hg) 17 4
PVR (dynes  s  cm5) 212 40
SVR (dynes  s  cm5) 1133 572
iPGI2, Inhaled prostacyclin; MAP, mean arterial blood pressure; PAP, pulm
pulmonary vascular resistance; SVR, systemic vascular resistance.
TABLE 6. Hemodynamic parameters for patients with right v
Variable Before iPGI2
PaO2/FIO2 ratio 287 157
MAP (mm Hg) 78 11
PAP (mm Hg) 34 10
MPAP/MAP ratio 0.43 0.12
CI (L · min1 · m2) 1.9 0.3
CVP (mm Hg) 21 5
Wedge (mm Hg) 18 2
PVR (dynes  s  cm5) 321 130
SVR (dynes · s  cm5) 1338 549
iPGI2, Inhaled prostacyclin; MAP, mean arterial blood pressure; PAP, pulmo
CVP, central venous pressure; PVR, pulmonary vascular resistance; SVR,
TABLE 7. Hemodynamic parameters for patients with righ
Variable Before PGI2
PaO2/FIO2 ratio 250 86
MAP (mm Hg) 80 11
PAP (mm Hg) 34 11
MPAP/MAP ratio 0.42 0.12
CI (L · min1 · m2) 1.9 0.3
CVP (mm Hg) 20 5
Wedge (mm Hg) 17 1.4
PVR (dynes  s  cm5) 202 18
SVR (dynes  s  cm5) 1231 518
iPGI2, Inhaled prostacyclin; MAP, mean arterial blood pressure; PAP, pulmo
CVP, central venous pressure; PVR, pulmonary vascular resistance; SVR,· min , even though significant levels of its metabolite
The Journal of Thoracic6-keto-prostaglandin F1 were detected.14 At the dose
ranges used in our study and in others, not enough PGI2
reaches the systemic circulation to cause significant vaso-
dilation. To maintain ease of administration and considering
the principles of inhalational drug delivery, we elected to
use a concentration-based rather than a weight-based pro-
tocol. Even at the highest concentration (20,000 ng/mL),
this amounted to an average of 37 ng · kg1 · min1. On the
basis of previously published dose-response studies, this
dose is well below the recommended safe inhalational dose
1 1 14,29
ry hypertension: baseline and after 4 to 6 h on iPGI2
4 to 6 h after n P value
302 166 37 .442
78 11 89 .16
25 8 86 .001
0.33 0.13 86 .001
2.9 0.8 33 .042
13 6 67 .001
16 5 6 .615
157 38 5 .078
931 249 22 .131
y artery pressure; CI, cardiac index; CVP, central venous pressure; PVR,
icular dysfunction: baseline and after the initiation of iPGI2
After iPGI2 n P value
357 134 7 .11
81 11 16 .356
29 10 15 .007
0.35 0.11 15 .002
2.2 0.6 12 .036
19 6 16 .058
17 3 6 .135
243 130 6 .05
1104 407 10 .014
rtery pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index;
mic vascular resistance.
tricular dysfunction: baseline and after 4 to 6 h on iPGI2
4 to 6 h after n P value
284 105 5 .552
72 7 13 .056
24 9 13 .002
0.34 0.14 13 .032
2.6 0.6 7 .038
14 6 13 .006
9.5 5 2 .205
147 8 2 .212
999 281 9 .216
rtery pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index;
mic vascular resistance.ona
onarentr
nary a
systet ven
nary a
systeof 50 ng · kg · min . The beneficial effects of the
and Cardiovascular Surgery ● Volume 127, Number 4 1063
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were lower than previously published.
Inhaled PGI2 has several advantages over iNO. It is easy
to administer and requires no special monitoring equipment
during administration. It can also safely be administered to
extubated patients via a face mask. This route of adminis-
tration was very well tolerated and did not cause any eye
irritation or sore throat, unlike iNO, which can cause met-
hemoglobinemia and buildup of oxygen free radicals and
nitrogen dioxide.3 Inhaled PGI2 does not have toxic metab-
olites that require monitoring. It is stored in a crystallized
powder form at room temperature, its final preparation with
the special glycine diluent is fast and easy, and it is readily
available.
There are certain precautions that have to be considered
when administering iPGI2. The final preparation has to be
shielded from light because of the potential for light deg-
TABLE 8. Effect of inhaled prostacyclin (iPGI2) on hemody
Variable Before PGI2
PaO2/FIO2 ratio 260 186
MAP (mm Hg) 77 12
MPAP (mm Hg) 35 9
MPAP/MAP ratio 0.47 0.14
CI (L · min1 · m2) 2.6 0.9
CVP (mm Hg) 18 7
Wedge (mm Hg) 18 2
PVR (dynes  s  cm5) 335 160
SVR (dynes  s  cm5) 1255 534
SvO2 (%) 70 14
FIO2, Fraction of inspired oxygen; MAP, mean arterial blood pressure; MP
pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular re
*The small n in the number of wedge pressures and cardiac output meas
inability to obtain these parameters for a variety of reasons, including tric
wedge the catheter. See Discussion section.
TABLE 9. Effect of inhaled prostacyclin (iPGI2) on hemody
Variable Before PGI2
PaO2/FIO2 ratio 256 167
MAP (mm Hg) 76 11
MPAP (mm Hg) 35 9
MPAP/MAP ratio 0.47 0.14
Cardiac output (L/min) 4.6 1.5
CI (L · min1 · m2) 2.5 0.8
CVP (mm Hg) 18 6
Wedge (mm Hg) 17 4
PVR (dynes  s  cm5) 209 37
SVR (dynes  s  cm5) 1143 553
SvO2 (%) 69 12
FIO2, Fraction of inspired oxygen; MAP, mean arterial blood pressure; MP
pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular re
*The small n in the number of wedge pressures and cardiac output meas
inability to obtain these parameters for a variety of reasons, including tric
wedge the catheter. See Discussion section.radation. Care has to be taken during transport to prevent
1064 The Journal of Thoracic and Cardiovascular Surgery ● Apraccidental spilling of the drug down the inspiratory limb
into the patient’s trachea. Another disadvantage of iPGI2 is
the inability to adequately deliver the nebulized drug to
patients in whom large-volume pulmonary edema develops.
As previously mentioned, the glycine buffer makes the
aerosol “sticky.” Filters on ventilators and BIPAP machines
therefore need to be frequently changed to prevent the
development of a stuck ventilator valve and auto-PEEP.
We have demonstrated that there are potentially large
cost savings when iPGI2 is used instead of iNO. These cost
savings would be even more substantial if the costs associ-
ated with monitoring for iNO toxicity were considered. The
relatively low cost, together with the excellent safety pro-
file, may allow for the use of iPGI2 in many patients in
whom iNO might not have been considered because of the
enormous costs currently associated with it. Inhaled NO
should still be readily available in cases in which patients do
ic parameters: baseline and after the initiation of iPGI2*
After PGI2 n P value
290 173 68 .075
78 11 125 .371
30 8 116 .001
0.39 0.13 116 .001
2.7 0.9 37 .113
17 8 91 .113
18 3 13 .802
246 112 13 .015
1121 405 24 .116
72 10 24 .332
ean pulmonary artery pressure; CI, cardiac index; CVP, central venous
ce; SvO2, mixed venous oxygen saturation.
ents (and hence derived parameters, such as PVR and SVR) reflects the
regurgitation (inaccurate, meaningless cardiac output) or the inability to
ic parameters: baseline and after 4 to 6 h on iPGI2*
4 to 6 h after n P value
281 164 43 .269
78 11 98 .253
24 8 92 .001
0.32 0.12 92 .001
5.3 1.6 36 .037
2.9 0.8 36 .036
13 6 73 .001
15 5 7 .424
156 34 6 .044
961 265 24 .137
69 11 24 .708
ean pulmonary artery pressure; CI, cardiac index; CVP, central venous
ce; SvO2, mixed venous oxygen saturation.
ents (and hence derived parameters, such as PVR and SVR) reflects the
regurgitation (inaccurate, meaningless cardiac output) or the inability tonam
AP, m
sistan
urem
uspidnam
AP, m
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urem
uspidnot respond to iPGI2. Similarly, in patients with severe
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Ppulmonary hypertension or refractory hypoxemia, these 2
agents combined, may provide additive effects.30
There are several limitations to the study. There was no
control group in our study, nor did we directly compare
iPGI2 with iNO. We did not believe that a control or placebo
group could be used in these critically ill patients, nor could
we stop the agent to allow patients to serve as their own
controls. However, this has previously been addressed in
other studies, albeit in small numbers of patients.8,12,13,20-22
Another limitation is that there are many confounding vari-
ables that affect the hemodynamic parameters that we mea-
sured. We did not standardize the intraoperative and anes-
thetic management or the postoperative critical care,
including vasoactive drug strategies and ventilation strate-
gies. This would not have been possible, considering the
heterogeneous group of patients. As a result, not all the
changes observed in our study may be attributable to iPGI2.
It is likely that the immediate changes (before and after) are
linked to iPGI2 but that some of the changes seen 4 to 6
hours after initiation of the drug were due to confounding
variables and the natural history of the pathophysiological
process. For example, a decrease in CVP may have been
due to a decrease in volume status or an improvement in
right ventricular function. Similarly, the decrease in MPAP
may be due to an improvement in many of the factors that
are known to affect pulmonary artery pressures, including
oxygenation, CO2 levels, acid-base status, functional resid-
ual capacity, vasopressor use, and shivering. Another limi-
tation is that we do not have complete data for some
variables, such as pulmonary vascular resistance, wedge
pressure, and CVP, at the 4- to 6-hour time point. This is
due to a number of factors that commonly occur in these
patients. First, some of the patients were already weaned
from iPGI2 by the time of the 4- to 6-hour measurements.
Second, it is a safe and common intensive care unit practice
that the pulmonary artery catheter is not wedged in patients
who have a high risk for potential pulmonary artery rupture,
eg, patients with pulmonary hypertension. Third, many of
the patients in this study are at risk for tricuspid regurgita-
tion, such as those with pulmonary hypertension and right
ventricular dysfunction. Thermodilution measurements of
cardiac output are inaccurate in the presence of tricuspid
regurgitation. Therefore, all those derived variables that rely
on cardiac output, such as pulmonary vascular resistance,
may be inaccurate. The only way to reliably measure flow in
these circumstances is to use a technology that is indepen-
dent of tricuspid regurgitation.
In summary, iPGI2 seems to be a safe, effective, and
cost-effective selective pulmonary artery vasodilator in this
large and diverse group of cardiothoracic surgery patients.
Although the route of delivery has not yet been FDA ap-
proved, this feasibility study now adds to the preponderance
The Journal of Thoracicof evidence that shows that the inhalational use of PGI2 is
an acceptable alternative to iNO.
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Discussion
Dr David Fullerton (Chicago, Ill). You have a very large group of
patients here. It is not common that one sees a surgical study of any
kind with this number of patients, and as your data highlight, it is
not rare to find pulmonary hypertension either with or without
hypoxemia in a very broad spectrum of both cardiac and thoracic
surgical patients. When it is severe, as in your study, it can be a
very, very difficult problem to treat, and for that reason it is very
important that we continue to pursue pharmacologic strategies to
help us treat these people.
1066 The Journal of Thoracic and Cardiovascular Surgery ● AprI think that what you have described for us is your clinical
experience with this agent in treating a very complicated group of
patients, so it is perfectly appropriate and it is perfectly under-
standable that you do have a heterogeneous group of patients. It is
for that reason that you also have the inability in this sort of a
project to control many of the other variables that may impact
PAP, such as acid-base status, ventilator management, depth of
anesthesia, and the administration of other vasoactive drugs.
Despite those limitations, I am intrigued that the agent works.
I am also very impressed that it seems easy to administer. It seems
very safe to administer, and it is certainly inexpensive. As you
begin to refine your knowledge of this, there are a couple of
questions that I do have for you.
Obviously we need a selective pulmonary vasodilator, and your
data suggest—acknowledging the difficulty in acquiring full data
sets with studies of this nature, your data nonetheless suggest that
the agent selectively vasorelaxes the pulmonary circulation, but 1
question is—these patients were also receiving a variety of other
vasoactive drugs given their critical illness. Do you have any
experience in administering inhaled prostacyclin in the absence of
any other vasoconstrictors that would be a little more conclusive in
its pulmonary vasoselectivity?
Dr Moazami. Since, as you mentioned, Dr Fullerton, this was
a clinical study, it is very difficult to tease out how inhaled
prostacyclin may have affected the pulmonary pressures given that
other agents, including milrinone and other vasodilators, were also
being used concomitantly. In many cases the inhaled prostacyclin
was started in the operating room after all those maneuvers had
been done, and we did not see a clinical response. However, I do
not have the data available on that, but interestingly, about 3
months ago there was an article from the Montreal Heart Institute
where they looked at exactly what you suggested. They had 20
patients and they randomized them to either prostacyclin or pla-
cebo, and during surgery they made all these measurements before
induction of anesthesia and after induction of anesthesia, and then
they administered prostacyclin before the patients went on cardio-
pulmonary bypass, made those measurements, and then made their
calculations. In fact, that study also conclusively shows that the
MPAP decreases without any other agent being on board. Now that
is a very different population of patients from those that we treated
(after cardiopulmonary bypass).
Dr Fullerton. My second question is as follows. One way to
address these problems in these kinds of studies is to permit each
patient to serve as his or her own control and collect hemodynamic
data, start the drug, reach a steady state, see if there has been any
sort of benefit from the drug, and then stop the drug temporarily.
This has a very short half-life. And see if the hemodynamic
condition returns to baseline or exactly what happens and then
rechallenge the patient with the drug in order to see if the salutary
benefits are attributable to the drug, or there are so many other
variables changing that perhaps 1 of them actually accounted for
the hemodynamic data. Do you have any experience with that?
Dr Moazami. We do have experience with it. Actually, since
we have had such a positive experience with inhaled prostacyclin,
we now use it as our first agent of choice for the treatment of that
condition. I think the condition that you are referring to is probably
going to be best studied in the postoperative patient in whom we
have to start this agent and everything else has been stabilized.
il 2004
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started during surgery, it is incredibly difficult to sort out those
factors. We certainly have the data available, and maybe it would
be interesting to get the patients who were just started after surgery
where everything else had already been in place and we just started
inhaled prostacyclin and see what the effect is. We certainly haveThe Journal of Thoracicor cross over to nitric oxide, but certainly those are important
questions that we can address. As mentioned, we have seen such a
clinical benefit from it that now we use it routinely, and although
this report is on 126 patients, we now have experience of more
than 150 patients in whom we have used it.
Dr Fullerton. Congratulations.CS
Pnot done it where we would start and then stop and then start again Dr. Moazami. Thank you.and Cardiovascular Surgery ● Volume 127, Number 4 1067
